{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:55:01Z","timestamp":1762505701410,"version":"3.44.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1016\/j.urology.2010.07.526","type":"journal-article","created":{"date-parts":[[2011,1,9]],"date-time":"2011-01-09T04:12:52Z","timestamp":1294546372000},"page":"763.e1-763.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["ProPSA and Diagnostic Biopsy Tissue DNA Content Combination Improves Accuracy to Predict Need for Prostate Cancer Treatment Among Men Enrolled in an Active Surveillance Program"],"prefix":"10.1016","volume":"77","author":[{"given":"Sumit","family":"Isharwal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danil V.","family":"Makarov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori J.","family":"Sokoll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Landis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cameron","family":"Marlow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan I.","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan W.","family":"Partin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Ballentine","family":"Carter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert W.","family":"Veltri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2010.07.526_bib1","first-page":"225","article-title":"Cancer statistics","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urology.2010.07.526_bib2","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/jnci\/95.12.868","article-title":"Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for prostate cancer","volume":"95","author":"Draisma","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urology.2010.07.526_bib3","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","article-title":"Screening and prostate-cancer mortality in a randomized European study","volume":"360","author":"Schroder","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2010.07.526_bib4","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1056\/NEJMoa0810696","article-title":"Mortality results from a randomized prostate-cancer screening trial","volume":"360","author":"Andriole","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2010.07.526_bib5","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1016\/j.juro.2007.08.039","article-title":"Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience","volume":"178","author":"Carter","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2010.07.526_bib6","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1001\/jama.1994.03510290050036","article-title":"Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer","volume":"271","author":"Epstein","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.urology.2010.07.526_bib7","doi-asserted-by":"crossref","first-page":"240","DOI":"10.6004\/jnccn.2010.0016","article-title":"NCCN clinical practice guidelines in oncology: prostate cancer early detection","volume":"8","author":"Kawachi","year":"2010","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.urology.2010.07.526_bib8","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1464-410X.2009.08791.x","article-title":"DNA content in the diagnostic biopsy for benign-adjacent and cancer-tissue areas predicts the need for treatment in men with T1c prostate cancer undergoing surveillance in an expectant management programme","volume":"105","author":"Isharwal","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2010.07.526_bib9","doi-asserted-by":"crossref","first-page":"7316","DOI":"10.1158\/1078-0432.CCR-09-1263","article-title":"Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer","volume":"15","author":"Makarov","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urology.2010.07.526_bib10","first-page":"957","article-title":"Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry","volume":"61","author":"Peter","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.urology.2010.07.526_bib11","unstructured":"Weinzierl CF, Su SX, Pierson TB, et al. Measuring [\u22122]proPSA in serum: analytical performance of the Access p2PSA assay from Beckman Coulter. Presented at the Annual Meeting of the American Association for Clinical Chemistry, abstract C-38, 2007."},{"key":"10.1016\/j.urology.2010.07.526_bib12","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1001\/jama.1982.03320430047030","article-title":"Evaluating the yield of medical tests","volume":"247","author":"Harrell","year":"1982","journal-title":"JAMA"},{"key":"10.1016\/j.urology.2010.07.526_bib13","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1093\/jnci\/djn255","article-title":"Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group 4 randomized trial","volume":"100","author":"Bill-Axelson","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urology.2010.07.526_bib14","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/ijc.22161","article-title":"PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section","volume":"120","author":"Khatami","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.urology.2010.07.526_bib15","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S0022-5347(05)67288-6","article-title":"p53 accumulation associated with Bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting","volume":"164","author":"Borre","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2010.07.526_bib16","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/pcan.2008.47","article-title":"Biopsy tissue microarray study of Ki-67 expression in untreated, localized prostate cancer managed by active surveillance","volume":"12","author":"Jhavar","year":"2009","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.urology.2010.07.526_bib17","first-page":"1882","article-title":"Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting","volume":"6","author":"Borre","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urology.2010.07.526_bib18","doi-asserted-by":"crossref","first-page":"4596","DOI":"10.1038\/sj.onc.1210237","article-title":"TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort","volume":"26","author":"Demichelis","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.urology.2010.07.526_bib19","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.eururo.2008.11.051","article-title":"A study of diffusion-weighted magnetic resonance imaging in men with untreated localised prostate cancer on active surveillance","volume":"56","author":"van As","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2010.07.526_bib20","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.juro.2009.10.003","article-title":"Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program","volume":"183","author":"Tosoian","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2010.07.526_bib21","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1200\/JCO.2009.25.7311","article-title":"Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a Prostate Cancer Surveillance Program","volume":"28","author":"Ross","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2010.07.526_bib22","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S0090-4295(02)02398-1","article-title":"Proenzyme PSA for the early detection of prostate cancer in the 2.5-4.0 ng\/mL total PSA range: preliminary analysis","volume":"61","author":"Sokoll","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.urology.2010.07.526_bib23","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1158\/1055-9965.EPI-10-0007","article-title":"A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [\u22122]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness","volume":"19","author":"Sokoll","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.urology.2010.07.526_bib24","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.juro.2009.12.056","article-title":"[\u22122]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study","volume":"183","author":"Le","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2010.07.526_bib25","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1002\/1097-0142(19930901)72:5<1692::AID-CNCR2820720533>3.0.CO;2-8","article-title":"Significance of abnormal diploid DNA histograms in localized prostate cancer and adjacent benign prostatic tissue","volume":"72","author":"Deitch","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2010.07.526_bib26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1471-2407-5-45","article-title":"Differences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donors","volume":"5","author":"Chandran","year":"2005","journal-title":"BMC Cancer"},{"key":"10.1016\/j.urology.2010.07.526_bib27","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1002\/ijc.23838","article-title":"Prognostic value of Her-2\/neu and DNA index for progression, metastasis and prostate cancer-specific death in men with long-term follow-up after radical prostatectomy","volume":"123","author":"Isharwal","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.urology.2010.07.526_bib28","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.urology.2008.09.060","article-title":"DNA ploidy as surrogate for biopsy Gleason score for preoperative organ versus nonorgan-confined prostate cancer prediction","volume":"73","author":"Isharwal","year":"2009","journal-title":"Urology"},{"issue":"suppl 2","key":"10.1016\/j.urology.2010.07.526_bib29","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1159\/000474709","article-title":"Nuclear deoxyribonucleic acid determination in patients with prostate carcinomas: clinical research and application","volume":"23","author":"Tribukait","year":"1993","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2010.07.526_bib30","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.eururo.2007.04.002","article-title":"The 20-yr outcome in patients with well- or moderately differentiated clinically localized prostate cancer diagnosed in the pre-PSA era: the prognostic value of tumour ploidy and comorbidity","volume":"52","author":"Adolfsson","year":"2007","journal-title":"Eur Urol"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429510016602?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429510016602?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T01:52:51Z","timestamp":1758765171000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429510016602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S0090429510016602"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2010.07.526","relation":{},"ISSN":["0090-4295"],"issn-type":[{"type":"print","value":"0090-4295"}],"subject":[],"published":{"date-parts":[[2011,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ProPSA and Diagnostic Biopsy Tissue DNA Content Combination Improves Accuracy to Predict Need for Prostate Cancer Treatment Among Men Enrolled in an Active Surveillance Program","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2010.07.526","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}